Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review
British Journal of Pharmacology · 2026-07-20
DOI: 10.1111/bph.70610 ↗At a glance
Übersichtsarbeit in British Journal of Pharmacology, published online on 2026-07-20. Written by Fabian Voß and 3 co-authors. Institution: Department of Cardiology, Pulmonology and Vascular Medicine, Heinrich-Heine University Düsseldorf, Medical Faculty, Düsseldorf, Germany. 110 references. The full text is freely available (open access, CC BY 4.0).
Topics: Herzinsuffizienz
Abstract (original language)
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock. Whereas anthracycline‐based and human epidermal growth receptor 2 (HER2)‐targeted therapies remain the most extensively studied causes, newer targeted agents and immune‐based therapies introduce additional, mechanistically distinct cardiotoxic phenotypes, including endothelial dysfunction and afterload‐driven heart failure (vascular endothelial growth factor [VEGF]‐pathway inhibitors, proteasome inhibitors), arrhythmia‐associated cardiac dysfunction (Bruton tyrosine kinase inhibitors) and inflammation‐mediated myocardial depression in the context of cytokine release syndromes (chimeric antigen receptor T [CAR‐T] cells and bispecific antibodies). This narrative review summarises the rationale and available evidence for the preventive use of conventional heart failure therapies across this evolving landscape. It further highlights current gaps in knowledge, especially regarding modern heart failure therapies and modern immune‐mediated oncological therapies.
Subjects
Author keywords
Authors and institutions
- Department of Cardiology, Pulmonology and Vascular Medicine, Heinrich-Heine University Düsseldorf, Medical Faculty, Düsseldorf, Germany.
- CARID (Cardiovascular Research Institute Düsseldorf), Düsseldorf, Germany.
Cite
APA
Voß, F., Goerke, P., Kelm, M., & Polzin, A. (2026). Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review. British Journal of Pharmacology. https://doi.org/10.1111/bph.70610
Vancouver
Voß F, Goerke P, Kelm M, Polzin A. Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review. British Journal of Pharmacology. 2026. doi:10.1111/bph.70610
BibTeX
@article{Vo2026,
author = {Voß, Fabian and Goerke, Paul and Kelm, Malte and Polzin, Amin},
title = {Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review},
journal = {British Journal of Pharmacology},
year = {2026},
doi = {10.1111/bph.70610}
}
EUVIMED